Metabolic Research Bundle x 9 Vials (MOTS-c 10mg / 5-Amino-1MQ 50mg / AOD-9604 5mg)

Each member of this bundle sits at a different point along the route from energy status to fat handling. MOTS-c belongs to the sensing end, studied as a mitochondrial signal that engages AMPK, the cell’s main energy gauge. 5-Amino-1MQ belongs in the middle, at cofactor supply: blocking NNMT spares nicotinamide for NAD+ salvage and saves methyl groups. AOD-9604 belongs to the output end, studied in adipocytes for lipolysis and lipid synthesis. A design using all three can therefore ask layered questions. Does raising cellular NAD+ change how cells respond to an AMPK-engaging signal? Does a lipolysis readout behave differently when energy sensing is already switched on? Because the three mechanisms barely overlap, any interaction observed is more informative than it would be for three compounds acting on one target.

Two members touch the same metabolic network from different ends. MOTS-c’s reported mechanism runs through the folate cycle, where blocking it lets AICAR accumulate, which in turn switches on AMPK. NNMT, the target of 5-Amino-1MQ, consumes S-adenosylmethionine, the methyl donor regenerated by the methionine cycle, which is itself linked to the folate cycle. Whether the two influence each other in the same cells has not, to our knowledge, been studied. A targeted metabolomics panel can test it: SAM and SAH (and their ratio), 1-methylnicotinamide as the direct product of NNMT, AICAR or ZMP, and NAD+. Including that panel in the combination arm turns a speculative link into a measurable one.

The published evidence does not sit in a single tissue. 5-Amino-1MQ and AOD-9604 have adipocyte data, including cultured fat-cell work for 5-Amino-1MQ, whereas MOTS-c’s strongest findings come from skeletal muscle. Two approaches handle that mismatch. One is differentiated 3T3-L1 adipocytes alongside a muscle line, linked by conditioned medium, which keeps each compound in its best-evidenced tissue. The other is a diet-induced obese mouse model, since all three have obese-mouse data, with muscle and fat analysed separately at the end. Useful readouts include glycerol release, lipid-droplet staining, 2-deoxyglucose uptake, phosphorylated AMPK and ACC, and NAD+/NADH. Staging three vials of each fits naturally: one set for short signalling experiments read within hours, one for multi-day differentiation runs where compounds are refreshed at each medium change, and one for confirming the key result.

The vial weights translate into very different molecule counts. A 10mg MOTS-c vial (about 2,174.6 g/mol) holds roughly 4.6 micromoles and a 5mg AOD-9604 vial (about 1,815.1 g/mol) about 2.75 micromoles, while a 50mg 5-Amino-1MQ vial (about 286.1 g/mol as the iodide salt) holds nearly 175 micromoles, around 38 times the MOTS-c and 64 times the AOD-9604. About 27.8mg of that 50mg is the active cation; the rest is iodide. Small-molecule inhibitors are typically used at micromolar concentrations, well above the range used for signalling peptides, which explains the larger fill. Matching arms by molarity rather than milligrams keeps comparisons fair, and the net-content figure on each batch certificate is the right starting point for that sum.